In year 2 of SELECT-GCA, 6.0% of patients continuing upadacitinib flared vs 55.9% switched to placebo.
|Articles|January 27, 2022
How has COVID-19 Affected Rheumatic Diseases?
Author(s)Lana Pine
From physical activity levels, to T-cell immune responses and quality of life, COVID-19 has impacted the lives of patients with rheumatic diseases. Take 5 minutes to catch up on the latest COVID-19 news.
Advertisement
Advertisement
Related to this article
In phase 1 COMPARE, 4 of 6 patients with refractory RA achieved remission by week 36 following CD19 CAR T-cell therapy.
ACR 2026 data show 56.7% of patients with PsA met GLP-1 RA eligibility criteria, but only 15.7% were prescribed treatment.
Once-weekly retatrutide reduced WOMAC pain and body weight vs placebo in two phase 3 trials, with up to 69.6% of participants halving knee pain at week 68.
Two ACR Convergence 2026 studies tie GLP-1 receptor agonists to lower cardiovascular and mortality risk.
Two ACR 2026 abstracts report rising cardiovascular deaths in Sjögren syndrome and superior ESSDAI response with baricitinib vs hydroxychloroquine.
Kate Harnden, MBChB, PhD, discusses models predicting persistent arthritis after checkpoint inhibitor therapy, presented at EULAR 2026 and as an ACR plenary.
Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Retatrutide Cuts Knee OA Pain, With Philip Conaghan, MBBS, PhD
2
Bimekizumab Leads New Wave of PsA Comparative Data: Philip Mease, MD
3
CD19 CAR T Shows Early Remission in Treatment-Refractory RA
4
Adding Tirzepatide Improves PsA Control in Obesity: Philip Mease, MD
5